Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.
Elena Losina, PhD
Advertisement
Elena Losina, PhD is the codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital
Articles by Elena Losina, PhD
Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.
Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Sotatercept Indication for PAH
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Misinformation and Knowledge Gaps Undermine Vaccine Protection: Kristina Crothers, MD
4
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
5
